Neil Wishart

This inventor holds 15 USPTO granted patents and 10 published patent applications, plus 4 CIPO patents and 2 EPO patents. Top assignees: Abbvie Inc., Abbott Laboratories Corporation, Abbott Gmbh & Co Kg. Active years: 2003-2019.

USPTO Granted Patents = 15 (Patent Applications = 10)

% Patents Active = 66.7

CIPO Patents = 4 (Patent Applications = 9)

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 8.8

ph-index = 12

Forward Citations = 1,212(Granted Patents)

Location History:

Holden, MA (US) (2008)
Jefferson, MA (US) (2003 - 2019)

Company Filing History:

Abbott Laboratories Corporation

5. 1 out of 834,411

Other

patents

Years Active: 2003-2019

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE47221 - Tricyclic compounds (2019-02-04),

2. 9365579 - Tricyclic compounds (2016-06-14),

3. 8962629 - Tricyclic compounds (2015-02-24),

4. 8785639 - Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof (2014-07-22),

5. 8754107 - Aminopyrrolidines as chemokine receptor antagonists (2014-06-17),

6. 8735411 - Macrocyclic benzofused pyrimidine derivatives (2014-05-27),

7. 8637529 - [object Object] (2014-01-28),

8. 8426411 - Tricyclic compounds (2013-04-23),

9. 8008481 - Indazole compounds (2011-08-30),

10. 7985745 - Method for pain treatment (2011-07-26),

11. 7829570 - Substituted 4-amino isoxazolo[5,4-d]pyrimidines as kinase inhibitors (2010-11-09),

12. 7560552 - Thiopyrimidine and isothiazolopyrimidine kinase inhibitors (2009-07-14),

13. 7332497 - Pyrazolopyrimidines as therapeutic agents (2008-02-19),

14. 6921763 - Pyrazolopyrimidines as therapeutic agents (2005-07-26),

15. 6660744 - Pyrazolopyrimidines as therapeutic agents (2003-12-09),

Title: Innovator Neil Wishart: Pioneering Tricyclic Compounds for Healthcare

Introduction: Neil Wishart is a prominent inventor based in Jefferson, MA, known for his significant contributions to the field of pharmaceuticals. With a portfolio of 15 patents, he has made strides in developing innovative compounds that target immunological and oncological conditions.

Latest Patents: Neil Wishart's latest inventions focus on tricyclic compounds. These patents describe compounds of Formula (I) and Formula (II), along with their pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers, and isomers. The compounds are specifically designed to address various immunological and oncological conditions, demonstrating a commitment to advancing medical solutions.

Career Highlights: Throughout his career, Wishart has played an essential role in leading projects that culminated in the development of impactful healthcare solutions. His extensive experience allowed him to work with major companies like AbbVie Inc. and Abbott Laboratories, where he contributed to innovative pharmaceutical breakthroughs.

Collaborations: Neil has collaborated with notable colleagues, including Michael M. Friedman and David J. Calderwood. These partnerships have enriched his work, resulting in the successful development of novel compounds that aim to improve patient outcomes.

Conclusion: Neil Wishart exemplifies the spirit of innovation and dedication to advancing healthcare through his inventions and patents. As his work continues to evolve, he remains an influential figure in the development of tricyclic compounds that hold promise for treating complex medical conditions. His contributions serve as an inspiration for future inventors and researchers in the pharmaceutical field.